Abstract
Atopic dermatitis is a chronic-inflammatory skin disease with relapsing and remitting course, with a high prevalence (10-20 %) in children of western countries. For many decades, topical corticosteroids have been the mainstay of therapy for atopic dermatitis. After the introduction of calcineurin-inhibitors as a corticosteroid-free alternative, expectations were high. After the black-box-warning of the FDA, regarding potential theoretical risk for developing neoplasia under the treatment with calcineurin inhibitors, an uncertainty occurred among patients and physicians.
Translated title of the contribution | Current safety aspects of therapy with topical calcineurin inhibitors |
---|---|
Original language | German |
Journal | Haut |
Volume | 18 |
Issue number | 1 |
Pages (from-to) | 36-40 |
Number of pages | 5 |
ISSN | 0938-2216 |
Publication status | Published - 02.2007 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)